VCEL — Vericel Corp Ord
NASDAQ · Healthcare · Biotechnology
$40.84
+$0.34 (+0.84%)
Vericel Corp Ord (VCEL) is a biotechnology company listed on NASDAQ. It is led by Dominick C. Colangelo Esq., based in 64 Sidney Street, Cambridge, MA, United States, 02139, with about 357 employees. Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest reported VCEL revenue for 2025-09-30 was $67.5M. Net income was $5.1M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30. VCEL currently screens at market cap $2.10B and trailing P/E 834.8.
Use this VCEL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VCEL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VCEL SEC filings page. Lician reads the product cache first so this HTML stays unique to Vericel Corp Ord even when a live quote feed is slow.
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Key Statistics
Market Cap
$2.10B
Volume
465,665
Previous Close
$42.30
Day Range
$42.53 – $43.25
P/E Ratio
834.80
EPS
$0.20
Revenue
$237.22M
Net Income
$10.36M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+20.1%
Profit Margin
4.4%
Employees
357
VCEL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $237.22M | $197.52M | $164.37M | $156.18M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $10.36M | -$3.18M | -$16.71M | -$7.47M |
| EPS (Diluted) | $0.20 | -$0.07 | -$0.35 | -$0.16 |
Total Assets
$432.72M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$74.52M
Operating Cash Flow
$58.16M
Free Cash Flow
$0.00
Vericel Corp Ord Company Information
- CEO, President & Director
- Dominick C. Colangelo Esq.
- Headquarters
- 64 Sidney Street, Cambridge, MA, United States, 02139
- Website
- www.vcel.com
- Phone
- 617 588 5555
- IPO / Founded
- 1997-02-04
- Sector
- Healthcare
- Industry
- Biotechnology